Apertura Gene Therapy

General Information

Company Name

Founded Year

2021

Location (Offices)

New York, United States +1

Founders / Decision Makers

Number of Employees

Industries

Biotechnology, Health Care

Funding Stage

Series A

Social Media

Apertura Gene Therapy - Company Profile

Apertura Gene Therapy is a biotechnology company founded in 2021 and headquartered in the United States. The company's slogan, "Bringing the Future of Gene Therapy into Focus," reflects its focus on pioneering next-generation AAV gene therapies. Apertura aims to address debilitating diseases with limited treatment options by simultaneously engineering capsids, regulatory elements, and payloads. The company is built on technologies from the Broad Institute and Harvard University, and has received substantial support from Deerfield Management Company.

Apertura recently secured a significant $67.00M Series A investment from Deerfield Management on 26 April 2022. The company's location at the Cure in New York City strategically situates it within a thriving biotechnology and healthcare hub. With its innovative approach and strong financial backing, Apertura Gene Therapy is poised to make a substantial impact in the field of genetic medicine.

Taxonomy: Gene Therapy, AAV Gene Therapies, Capsid Engineering, Regulatory Elements, Payload Engineering, Genetic Medicine, Broad Institute, Harvard University, Deerfield Management Company, Biotech Startups, New York City, Innovation in Medicine